CN107043339B - 新交联试剂、大分子、治疗用偶联物及其合成方法 - Google Patents

新交联试剂、大分子、治疗用偶联物及其合成方法 Download PDF

Info

Publication number
CN107043339B
CN107043339B CN201710164951.6A CN201710164951A CN107043339B CN 107043339 B CN107043339 B CN 107043339B CN 201710164951 A CN201710164951 A CN 201710164951A CN 107043339 B CN107043339 B CN 107043339B
Authority
CN
China
Prior art keywords
independently selected
group
compound
alkyl
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710164951.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107043339A (zh
Inventor
黄玉梅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xi Mosai Biotechnology Co Ltd
Original Assignee
Xi Mosai Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xi Mosai Biotechnology Co Ltd filed Critical Xi Mosai Biotechnology Co Ltd
Publication of CN107043339A publication Critical patent/CN107043339A/zh
Application granted granted Critical
Publication of CN107043339B publication Critical patent/CN107043339B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D229/00—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms
    • C07D229/02—Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C291/00—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00
    • C07C291/02—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds
    • C07C291/04—Compounds containing carbon and nitrogen and having functional groups not covered by groups C07C201/00 - C07C281/00 containing nitrogen-oxide bonds containing amino-oxide bonds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polyethers (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201710164951.6A 2011-07-19 2012-07-18 新交联试剂、大分子、治疗用偶联物及其合成方法 Active CN107043339B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509296P 2011-07-19 2011-07-19
US61/509,296 2011-07-19
CN201280034231.3A CN104066451B (zh) 2011-07-19 2012-07-18 新交联试剂、大分子、治疗用偶联物及其合成方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280034231.3A Division CN104066451B (zh) 2011-07-19 2012-07-18 新交联试剂、大分子、治疗用偶联物及其合成方法

Publications (2)

Publication Number Publication Date
CN107043339A CN107043339A (zh) 2017-08-15
CN107043339B true CN107043339B (zh) 2019-09-06

Family

ID=46640108

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710164951.6A Active CN107043339B (zh) 2011-07-19 2012-07-18 新交联试剂、大分子、治疗用偶联物及其合成方法
CN201280034231.3A Active CN104066451B (zh) 2011-07-19 2012-07-18 新交联试剂、大分子、治疗用偶联物及其合成方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280034231.3A Active CN104066451B (zh) 2011-07-19 2012-07-18 新交联试剂、大分子、治疗用偶联物及其合成方法

Country Status (7)

Country Link
US (1) US8907079B2 (https=)
EP (1) EP2734238B1 (https=)
JP (1) JP6240599B2 (https=)
CN (2) CN107043339B (https=)
AU (1) AU2012284055B2 (https=)
CA (1) CA2841313C (https=)
WO (1) WO2013012961A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511150B2 (en) 2011-07-19 2016-12-06 CellMosaic, Inc. Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
WO2014134445A1 (en) * 2013-02-28 2014-09-04 Tufts Unversity Disulfide compounds for delivery of pharmaceutical agents
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
JP5924795B2 (ja) 2014-06-13 2016-05-25 テンボロン オイ 複合体
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
TWI648271B (zh) 2014-09-23 2019-01-21 日商住友電木股份有限公司 二氮環丙烯化合物及由其衍生之組成物
CN104560026A (zh) * 2014-12-25 2015-04-29 温州医科大学附属第二医院 一种活体卵巢癌组织的靶向muc1的荧光探针及其制备方法
WO2017060122A1 (en) * 2015-10-05 2017-04-13 Syngenta Participations Ag Methods of preserving the biological activity of ribonucleic acids
JP6486316B2 (ja) 2015-11-03 2019-03-20 財團法人工業技術研究院Ｉｎｄｕｓｔｒｉａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗体−薬物複合体（ａｄｃ）およびそれを形成するための方法
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
KR20210031848A (ko) 2017-09-05 2021-03-23 토크 테라퓨틱스, 인코포레이티드 가역적 링커 및 이의 용도
US12515382B2 (en) * 2018-02-16 2026-01-06 Zeon Corporation Production method for dip-molded article
US12258334B2 (en) * 2018-05-01 2025-03-25 Cellmosaic Inc. Branched sugar alcohol-based compounds, and compositions and methods thereof
CN109142330B (zh) * 2018-07-31 2020-09-11 漯河医学高等专科学校 ZnS-CeO2-WO3-Al2O3丙酮氰醇气体传感器材料的制备方法及丙酮氰醇气体传感器
CN109776625B (zh) * 2019-03-18 2022-08-23 南京江原安迪科正电子研究发展有限公司 一种d-甘露糖的合成方法
CA3137379A1 (en) * 2019-04-26 2020-10-29 Xlynx Materials Inc. Diazirine-based molecules and uses thereof
CN110563698A (zh) * 2019-07-25 2019-12-13 苏州昊帆生物股份有限公司 一种新型蛋白质交联剂及其制备方法
CN116635083A (zh) * 2020-12-22 2023-08-22 豪夫迈·罗氏有限公司 用于检测样品中的目标分析物的方法
EP4279502A4 (en) * 2021-01-18 2026-02-11 Ajinomoto Kk COMPOUND OR ITS SALT, AND ANTIBODIES THUS OBTAINED
US20220298399A1 (en) * 2021-03-19 2022-09-22 Facebook Technologies, Llc Synthesis and use of multi-functional diazirine adhesives for elastomer bonding
JP7717832B2 (ja) 2021-04-10 2025-08-04 ジェンマブ エー／エス Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
WO2022226317A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CN115043899B (zh) * 2022-05-24 2024-10-22 南开大学 双胺或胺与硫醇偶联的化合物及其制备方法和应用
CN117835778A (zh) * 2022-09-26 2024-04-05 清华大学 图案化量子点薄膜的制备方法、光电器件与电子设备
AU2024353316A1 (en) 2023-09-26 2026-03-26 Genmab A/S Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031244A1 (en) * 2002-10-04 2004-04-15 Glykos Finland Oy Novel carbohydrate compositions and a process of preparing same
US20080108557A1 (en) * 2004-09-29 2008-05-08 Novo Nordisk Healthcare A/G Modified Proteins
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
WO2010080817A2 (en) * 2009-01-06 2010-07-15 Utah State University Carbohydrate-cyclopamine conjugates as anticancer agents
US20100330608A1 (en) * 2005-04-28 2010-12-30 Postech Foundation Molecular transporters based on sugar and its analogues and processes for the preparation thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2258892A (en) * 1938-08-25 1941-10-14 Benjamin R Harris Ethers of polyglycerols
US2520670A (en) 1946-10-24 1950-08-29 Gen Mills Inc Polyglycerols
US2532036A (en) 1946-10-24 1950-11-28 Gen Mills Inc Process of preparing polyhydric alcohols
US2520671A (en) 1946-10-24 1950-08-29 Gen Mills Inc Polyhydroxy compounds
GB723244A (en) * 1951-04-10 1955-02-02 Unilever Ltd Improvements in or relating to surface-active agents
US4172094A (en) 1976-12-03 1979-10-23 Merck & Co., Inc. Polyamine compounds
DE4124283A1 (de) 1991-07-15 1993-01-21 Degussa Umesterung von peptiden
GB9121279D0 (en) 1991-10-08 1991-11-20 Cerestar Holding Bv Process for the production of aminopolyols
FR2701949B1 (fr) 1993-02-22 1997-01-24 Picardie Jules Verne Universit Procédé de synthèse de nouveaux composés disaccharidiques, sans jonction glycosidique, produits obtenus par ce procédé et leurs applications comme médicament tensioactif ou agent chélatant.
DE69419601T2 (de) 1993-03-17 1999-12-02 Kao Corp., Tokio/Tokyo Aminderivate und sie enthaltende dermatologische zubereitungen
EP1194037B1 (en) 1999-07-16 2004-08-18 Imperial Chemical Industries PLC Agrochemical compositions and surfactant compounds
KR100872884B1 (ko) * 2000-03-24 2008-12-10 바이오스피어 메디칼 인코포레이티드 능동 색전화용 미소구
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
US7919653B2 (en) 2002-07-30 2011-04-05 Reverse Proteomics Research Institute Co., Ltd. Method of inhibiting nonspecific interaction between molecules on solid phase support
ATE409048T1 (de) * 2002-10-08 2008-10-15 Fresenius Kabi De Gmbh Pharmazeutisch aktive oligosaccharid-conjugate
US7560231B2 (en) * 2002-12-20 2009-07-14 Roche Molecular Systems, Inc. Mannitol and glucitol derivatives
KR20060032140A (ko) 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
KR101237884B1 (ko) 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
US20080015142A1 (en) 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
US20070134243A1 (en) * 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
JP2008526864A (ja) 2005-01-06 2008-07-24 ネオス テクノロジーズ インコーポレイテッド 糖断片を用いる糖結合
EP1850878A2 (en) 2005-02-10 2007-11-07 Novo Nordisk A/S C-terminally pegylated growth hormones
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
HUE035853T2 (en) * 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
PL206420B1 (pl) 2006-08-03 2010-08-31 Politechnika Wroclawska Nowe pochodne disorbityloaminy i sposób ich otrzymywania
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
FR2906245A1 (fr) 2006-09-25 2008-03-28 Oreal Diamides hydroxyles agent d'hydratation de la peau
WO2008073463A2 (en) * 2006-12-11 2008-06-19 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
FR2921838A1 (fr) 2007-10-05 2009-04-10 Guerbet Sa Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile
JP2009249500A (ja) 2008-04-07 2009-10-29 Hakuto Co Ltd 重合性高分岐ポリマー及びその製造方法
EP2123304A1 (en) * 2008-05-23 2009-11-25 Freie Universität Berlin Compounds suited as nanocarriers for active agents and their use
CN102124086A (zh) 2008-07-31 2011-07-13 国际壳牌研究有限公司 聚(羟基羧酸)酰胺盐衍生物和包含它的润滑组合物
JP5702278B2 (ja) 2009-05-19 2015-04-15 日産化学工業株式会社 長鎖グリシルポリオール型ゲル化剤およびゲル

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031244A1 (en) * 2002-10-04 2004-04-15 Glykos Finland Oy Novel carbohydrate compositions and a process of preparing same
US20080108557A1 (en) * 2004-09-29 2008-05-08 Novo Nordisk Healthcare A/G Modified Proteins
US20100330608A1 (en) * 2005-04-28 2010-12-30 Postech Foundation Molecular transporters based on sugar and its analogues and processes for the preparation thereof
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
WO2010080817A2 (en) * 2009-01-06 2010-07-15 Utah State University Carbohydrate-cyclopamine conjugates as anticancer agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Eric S. Underbakke等.Isotope-Coded Affinity Tags with Tunable Reactivities for Protein Footprinting.《Angew. Chem. Int. Ed.》.2008,第47卷第9677-9680页.
Junkichi Iwasa等.Synthesis of photoaffinity and Tritium-labeled Grayanotoxin via Reductive Amination.《Biosci.Biotech.Biochem.》.1994,第58卷(第5期),第972-973页.

Also Published As

Publication number Publication date
EP2734238A2 (en) 2014-05-28
BR112014000324A8 (pt) 2019-01-29
US20140206903A1 (en) 2014-07-24
EP2734238B1 (en) 2020-02-19
AU2012284055B2 (en) 2017-09-07
CN104066451A (zh) 2014-09-24
US8907079B2 (en) 2014-12-09
BR112014000324A2 (pt) 2017-02-07
AU2012284055A1 (en) 2014-01-30
JP2014521319A (ja) 2014-08-28
WO2013012961A3 (en) 2013-08-01
WO2013012961A2 (en) 2013-01-24
CN107043339A (zh) 2017-08-15
CN104066451B (zh) 2017-04-05
JP6240599B2 (ja) 2017-11-29
CA2841313C (en) 2023-10-24
CA2841313A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
CN107043339B (zh) 新交联试剂、大分子、治疗用偶联物及其合成方法
US9907854B2 (en) Crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
CN112584871A (zh) 支化糖醇基化合物和组合物及其方法
JP2014521319A5 (https=)
Maier et al. Synthesis of antisense oligonucleotides conjugated to a multivalent carbohydrate cluster for cellular targeting
US8637711B2 (en) Selective and specific preparation of discrete PEG compounds
US7097856B2 (en) Dendrimeric support or carrier macromolecule
US20170072068A1 (en) Sulfamide linker, conjugates thereof, and methods of preparation
JP7042053B2 (ja) 分岐型ヘテロ単分散ポリエチレングリコール、その製造方法、及びその結合体
EP0850262B1 (en) Selectively functionalizable desdendrimers
JP2010521526A (ja) 多価ヘテロ二官能性ポリマーおよびその使用方法
KR20180022919A (ko) 헤테로형 단분산 폴리에틸렌글리콜, 헤테로형 단분산 폴리에틸렌글리콜 제조용 중간체, 그들의 제조 방법, 및 헤테로형 단분산 폴리에틸렌글리콜 결합체
CN121100004A (zh) 具有改进的t-连接子的反式-环辛烯
EP1594440B1 (en) The selective and specific preparation of discrete peg compounds
CN102803228B (zh) 酸不稳定触发子单元
Šebestík et al. Synthesis of dendrimers: Convergent and divergent approaches
CN102083847A (zh) 新型核酸转移系统
EP2420518A1 (en) Polycationic amphiphilic cyclooligosaccharides and the use thereof as molecular transporters
US11945838B2 (en) Method for synthesis of protein amphiphiles
AU3706499A (en) Method for the production of pentopyranosyl nucleosides
EP4314031B1 (en) Masked il12 protein
BR112014000324B1 (pt) Composto de álcool de açúcar monomérico e composto derivado de álcool de açúcar
CN121318932A (zh) 一种新型三荷载连接子的合成及其在偶联药物的应用
Zhang et al. Study on synthesis of multivalent neoglycoproteins and their binding properties to hepatic stellate cells
Milanese Cycloaddition reactions in

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant